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Introduction
Recent comprehensive researches on pathological 
and molecular patterns of breast cancer using advanced 
microarray technology and genetic detection tools 
have resulted in identifying new classification for 
this cancer (Colombo et al., 2011; Vuong et al., 
2014). In this stratification, the cancer subtypes vary 
according to their gene expression signatures leading 
different clinical outcome (Cardoso, 2003). The main 
definitive subgroups defined for breast cancer includes 
luminal subtypes A and B, the HER2-subtype, and 
basal-like subtype (Roulot et al., 2016). Based on positive 
or negative reception for hormones including estrogen or 
progesterone, these subtypes have classified as luminal 
A (positive for estrogen and progesterone receptors, 
but negative for HER-2/neu), luminal B (positive for 
estrogen and progesterone receptors, but manifested by 
the pattern of HER-2/neu+), non-luminal HER-2/neu+ 
(negative for both estrogen and progesterone receptors 
but with the pattern of HER-2/neu+) and triple negative 
pattern which is negative for all pointed receptors 
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(Lim et al., 2013; Skibinski and Kuperwasser, 2015). 
The interesting discover on these molecular pattern is 
the close relationship between these subtypes and both 
clinical prognosis and response to treatment approaches. 
Furthermore, this variation can help us to find out 
the exact etiology of breast cancer and its invasion. 
In fact, the heterogeneity of breast tumors molecular 
subtype may reflect its-related etiological pathways 
(Moriya et al., 2016). For instance, because both luminal 
subtypes A and B are positive for both estrogen and 
progesterone hormones, the main etiologies of these 
subtypes may be related to exposing these two hormones 
(Masood, 2016). More interestingly, due to close 
association between breast cancer subtypes and disease 
prognosis, the classic risk factors for this cancer leading 
poor disease prognosis may be linked to the molecular 
subtype of cancer (Akinyemiju et al., 2015).In fact, by 
assessing risk factors in relation to more homogenous 
subtypes we can identify novel risk profiles with 
combining both classic and molecular risk factors with 
the aim of better predicting disease prognosis and survival. 
The present study aimed to assess the association of 
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reproductive risk factors for breast cancer (including age, 
age at first pregnancy, history of abortion, duration of 
breastfeeding, and history of contraceptive use) and also 
tumor-related diameters with tumor molecular subtypes.
Materials and Methods
This bi-center cross-sectional study was performed 
on women with known breast cancer who referred to two 
great referral hospitals as the Comprehensive Cancer 
Centers in Tehran between 2006 and 2016. In total, 800 
cases with breast cancer were included into the study. 
All women reporting incident diagnoses of cancer were 
asked for permission to review their medical records to 
confirm the diagnosis and to classify cancers as in situ 
or invasive, by histologic type, size, and presence or 
absence of metastases. By reviewing the recorded files, 
the baseline information including classic risk factors for 
breast cancer age, size of tumor, age at first pregnancy, 
frequency of pregnancy, history of abortion, duration of 
breastfeeding, history of using oral contraceptives, and 
number of lymph nodes was collected. The information 
on molecular breast cancer subtypes were also extracted 
from the hospital recorded files that previously identified 
using immunohistochemical analysis by immune-staining 
for ER, PR, and HER2 molecules. In this regard, 
the subtypes were defined as luminal A (ER+ or PR+ and 
HER-2/neu−), luminal B (ER+ or PR+, HER-2/neu+), 
non-luminal HER-2/neu+ or HER-2 over expression 
(ER−, PR−, HER-2/neu+), and triple negative (ER−, PR−, 
and HER-2/ neu−). The study endpoint was to examine 
the relation between the clinical and tumor-related risk 
factors and various molecular subtypes of breast cancer. 
For statistical analysis, results were presented as 
mean ± standard deviation (SD) for quantitative variables 
and were summarized by frequency (percentage) for 
categorical variables. Continuous variables were compared 
using ANOVA test or Kruskal-Wallis H test whenever 
the data did not appear to have normal distribution or when 
the assumption of equal variances was violated across 
the study groups. Categorical variables were, on the other 
hand, compared using chi-square test. P values of ≤ 0.05 
were considered statistically significant. For the statistical 
analysis, the statistical software SPSS version 23.0 for 
windows (IBM, Armonk, New York) was used.
Results
The mean age of patients was 51.12 ± 11.72 years. 
Of 800 samples included for immunohistochemical 
analysis, 314 (39.3%) were positive for Luminal A 
subtype, 107 (13.4%) for Luminal B subtype, 153 (19.1%) 
for HER-2 over expression, and 226 (28.3%) for triple 
negative subtype. Regarding pathological types, the most 
common feature was IDC in 76.0% followed by ILC in 
13.3%, in situ in 4.8%, mixed in 4.0% and other types in 
2.0%. Overall, 14.2% had history of oral contraceptive use. 
As shown in (Table 1), those patients with HER-2 over 
expression pattern was significantly younger than other 
subgroups (p = 0.006). The mean size of tumor was more in 
those with luminal B subtypes (p < 0.001). Also, the mean 
age at first pregnancy was the lowest in luminal A subtype 
and the highest in triple negative subtype (p< 0.001). Also, 
the lowest and the highest number of gravity was revealed 
in triple negative and luminal A subtypes respectively with 
a significant difference across the subtypes (p = 0.001). 
The history of abortion was significantly found more 
in luminal B subtypes as compared to other molecular 
Item Luminal A         Luminal B HER-2 over expression Total physical activity
Age, year 52.32 ± 10.86 52.33 ± 12.23 48.85 ± 11.46 13.0
Size of tumor 2.55 ± 1.39 3.34 ± 4.10 2.46 ± 1.18 12.2
Number of positive node 2.55 ± 4.71 2.29 ± 4.08 2.28 ± 4.52 11.2
Age at first pregnancy, year 20.24 ± 6.18 21.19 ± 6.59 21.58 ± 5.28 14.5
Number of gravid 3.21 ± 1.96 3.12 ± 1.79 2.85 ± 1.43 14.7
Number of previous abortion 0.35 ± 0.83 0.92 ± 1.14 0.58 ± 0.82 11.8
Duration of breastfeeding
   Months 17.88 ± 8.19 16.11 ± 6.99 17.84 ± 7.08 13.1
Table 1.The Association between Class Risk Factors for Breast Cancer and Molecular Subtypes of the Tumor
Item Luminal A Luminal B HER-2 over expression Total physical activity
IDC 322 (72.5) 91 (77.1) 151 (74.4) 0.001
ILC 87 (19.6) 17 (14.4) 26 (12.8) 12.9
In Situ 13 (2.9) 4 (3.4) 14 (6.9) 12.5
Mixed 15 (3.4) 4 (3.4) 11 (5.4) 10.5
Others 7 (1.6) 2 (1.7) 1 (0.5) 16.2
IDC 322 (72.5) 91 (77.1) 151 (74.4) 15
ILC 87 (19.6) 17 (14.4) 26 (12.8) 10
In Situ 13 (2.9) 4 (3.4) 14 (6.9) 12.7
Table 2. Association between Pathological Diagnosis and Molecular Subtypes of the Tumor
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negative subtypes. In fact, each molecular subtype was 
specifically associated with specific reproductive risk 
factor. In other words, some hormonal risk factors were 
associated with hormone receptor negative subtypes. 
For instance, HER-2 over expression was more found 
in lower ages; and triple negative pattern was identified 
in those women with lower parity as well as in those 
with shorter breastfeeding. A number of previous studies 
have examined the association between breast cancer 
risk factors and tumor molecular subtypes. As shown by 
Turkoz et al., (2013) on Turkish women, the age of ≥40 
years was found to be a risk factor for both luminal A 
and HER-2 overexpressing subtypes. Women who were 
nulliparous or who had their first full-term pregnancy at 
age 30 years or older were at increased risk of luminal 
breast cancer. Also, breastfeeding was a protective factor 
for luminal subtype. However they found no significant 
differences between the risk of breast cancer subtypes 
and early menarche, late menopause, family history, 
postmenopausal obesity, oral contraceptive use, smoking, 
in vitro fertilization, and blood groups. In another studyl 
in USA (Gaudet et al., 2011), triple negative tumors were 
associated with breastfeeding duration, increased body 
size was more strongly associated with both luminal B 
and triple negative tumors, a history of benign breast 
disease was associated with increased risk of luminal 
A tumors and also a family history of breast cancer was 
a risk factor for luminal A tumors. In a study by Islam 
et al., (2012) on Japanese women with breast cancer, a 
significant association was observed between early age 
at menarche and risk of luminal disease, however, no 
significant differences in association with parity, age at 
first live birth, breastfeeding history, age at menopause, 
subtypes (p < 0.001). Moreover, the duration of 
breastfeeding was significantly shorter in those who 
were triple negative subtypes. However, the number 
of positive lymph nodes was not associated with the 
molecular subtypes of the tumor. Considering various 
pathological types (Table 2), the prominent molecular 
subtypes was triple negative in IDC diagnosis, in ILC was 
luminal A subtypes, and in mixed and in situ diagnoses 
was HER-2 over expression indicating a significant 
difference in the molecular subtypes of tumor and 
pathological diagnosis (p < 0.001). No association was 
revealed between the use of oral contraceptive and the 
molecular subtype of breast cancer (15.7% in luminal A, 
18.0% in luminal B, 16.3% in HER-2 over expression 
and 12.5% in triple negative subtypes, p = 0.665). Among 
all classic risk factors, only the age at first pregnancy 
was adversely associated with the presence of in situ 
diagnosis (Table 3). No association was found between 
the pathological type of tumor and history of oral 
contraceptive use (Table 4).
Discussion
In the present study of over 800 breast cancer subjects, 
some significant differences were revealed between 
some traditional risk factors for cancer and some specific 
molecular subtypes of the tumor. Among all reproductive 
risk factors initially assessed, young age was associated 
with HER-2 over expression pattern, more tumor size 
with luminal B subtype, lower age at first pregnancy with 
luminal A subtype, lower number of parity with triple 
negative pattern, the history of abortion with luminal B 
subtype, and shorter duration of breastfeeding with triple 
Item IDC ILC In Situ 0.001 Total physical activity
Age, year 50.71 ± 11.34 52.90 ± 12.25 52.95 ± 11.35 12.9
Size of tumor 2.63 ± 1.51 2.72 ± 1.21 2.69 ± 1.20 12.5
Number of positive node 2.46 ± 4.42 2.75 ± 4.05 2.03 ± 4.06 10.5
Age at first pregnancy, year 21.70 ± 5.56 19.92 ± 5.91 19.58 ± 5.73 16.2
Number of gravid 2.78 ± 1.66 3.33 ± 2.29 2.89 ± 1.84 15.0
Number of previous abortion 0.66 ± 0.88 0.56 ± 0.84 1.00 ± 1.52 10.0
Duration of breastfeeding,
   Months 16.18 ± 7.25 17.90 ± 7.03 15.87 ± 8.28 12.7
Table 3. The Association between Class Risk Factors for Breast Cancer and Pathological Diagnosis of the Tumor
Table 4. The Association between Class Risk Factors for Breast Cancer and Pathological Diagnosis of the Tumor
Type OCP use (+) OCP use (-) Type Total physical activity
IDC 540 (76.8%) 67 (69.1%) IDC -
ILC 89 (12.7%) 17 (17.5%) ILC 12.9
In Situ 36 (5.1%) 6 (6.2%) In Situ 12.5
Mixed 23 (3.3%) 7 (7.2%) Mixed 10.5
Others 15 (2.1%) 0 (0.0%) Others 16.2
Type OCP use (+) OCP use (-) Type 15
IDC 540 (76.8%) 67 (69.1%) IDC 10
ILC 89 (12.7%) 17 (17.5%) ILC 12.7
In Situ 36 (5.1%) 6 (6.2%) In Situ 0.001
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or synthetic hormonal use were seen across molecular 
subtypes of breast cancer. The Polish Breast Cancer 
Study also found that most established breast cancer 
risk factors such as age at menarche was associated with 
luminal A tumors (Yang et al., 2007). They also showed 
that having a family history of breast cancer was a risk 
factor for almost all subtypes although the magnitude of 
the effect was greatest for HER2-type breast cancers. Also, 
in a large study on 1,424 breast cancer cases in the USA, 
it was revealed that increasing parity was associated with 
reduced risk of luminal A tumors. Summing the studies 
in different geographical regions leads to the fact that 
various reproductive risk factors may be associated with 
specific molecular subtypes of the tumors and more 
interestingly these associations are considerably different 
among different patients’ populations, emphasizing strong 
effect of gene variants on these associations. In fact, with 
respect to the etiological pathways for each pathological 
types of breast cancer, each correlative reproductive risk 
profile may act as a major ring of etiological chain for 
each pathological type of tumor in special population and 
thus this heterogeneity across different populations should 
be deeply examined in each population.
One of the main goals of the present study was to find 
out whether those molecular subtypes of breast cancer with 
poorer outcome and survival (such as triple negative subtype) 
are accompanied with poorer manifestations, and 
better molecular subtype was associated with better 
reproductive factors. In regards to that, we could show that 
the subtype of triple negative is associated with shorter 
duration of breastfeeding, higher age at first pregnancy 
and lower parity, also the luminal A subtype with best 
prognosis between other subtypes was related with good 
reproductive factors like younger age at first pregnancy 
and more parity but we could not find a relation between 
duration of feeding and this subtype.
It has been well demonstrated that the risk for 
developing triple negative subtype of tumor varies widely 
with pattern of breastfeeding and parity. Concerning that, 
it has been shown that the subtype of triple negative 
is manifested more in younger ages, and in those with 
shorter duration of breastfeeding (Millikan et al., 2008), 
however some other studies could not demonstrate these 
associations (Yang et al., 2007, Phipps et al., 2008).
In conclusion, in total, breastfeeding and parity 
have been well identified as potential protective 
factors against breast cancer and thus the lack of these 
factors can lead to poorer tumor-related outcome and 
shorter patients’ survival (Morris, 2009). More parity 
and younger age in first pregnancy were related with 
luminal A subtype. In other words, shorter breastfeeding 
and primiparity are negative risk factors leading to an 
increased likelihood of breast cancer especially molecular 
subtypes with poorer outcome such as triple negative type 
in our study.
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